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Abstract 
Background: The incidence of metabolic syndrome has been rising in the Iran population. In parallel, vitamin D 
deficiency has also been increasing in Iran. This study aims to explore the association of vitamin D serum 
concentrations with metabolic syndrome and its components in the Iranian population. Materials and Methods: A 
case-control study was managed. We enrolled 110 metabolic syndrome patients, according to the National 
Cholesterol Education Program Adult Treatment Panel III (ATP III) criteria as a case group and 130 healthy 
individuals as a control group. The serum level of 25-hydroxy vitamin D (25 (OH)D), lipid profile, and fasting blood 
glucose(FBS) status were determined using a commercially available ELISA method. Enzymatic methods 
determined total cholesterol (Chol), high-density lipoprotein (HDL) cholesterol, low-density lipoprotein (LDL), and 
triglyceride (TG) levels. Results: In case group, the prevalence rate of 25 (OH)D deficiency (<10 ng/mL) was 10%, 
25 (OH)D insufficiency (10–29 ng/mL) was 71.0%, and 25 (OH)D sufficiency (>30 ng/mL) was 19.0%. A non-
significant association between Chol level and age was noted (p=0.46, p=0.124). The levels of FBS and TG were 
significantly higher, and the levels of 25 (OH)D, LDL, and HDL were significantly lower in the case of the group 
compared to the control group. Conclusion: We found that the serum level of 25 (OH)D in patients with metabolic 
syndrome is lower than in the healthy group, and a low level of 25 (OH)D is related to increased risk of metabolic 
syndrome and its components. 
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Metabolic syndrome, also known as syndrome 
X, is a complex metabolic disorder with known clinical 
findings, including hyperglycemia, central obesity, 
dyslipidemia, insulin resistance, and high blood 
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pressure, which are the potent predictors of diabetes 
and cardiovascular diseases (1). According to the 
National Cholesterol Education Program Adult 
Treatment Panel III (ATP III) criteria, the existence of 
at least three items of following disorders considered 
as a metabolic syndrome: abdominal obesity ≥ 88 cm 
for female and ≥ 102 cm for male, high-density 
lipoprotein cholesterol (HDL-c) levels < 50 mg/dl for 
female and < 40 mg/dl for male, increased triglyceride 
level ≥ 150 mg/dl, fasting blood sugar (FBS) > 100 
mg/dl, high blood pressure (systolic blood pressure ≥ 
130 mmHg or diastolic blood pressure ≥ 85 mmHg) 
(2). The prevalence of metabolic syndrome is 
estimated at 27.46%–33.7% in Iranian adults. Besides, 
the rising prevalence of metabolic syndrome is due to 
physical inactivity, increasing age, unhealthy food 
habits, and obesity involved both developed and 
developing societies. (3).  
Accumulating evidence suggests that low 
serum levels of 25 (OH) D are also related to metabolic 
syndrome pathogenesis and its components (4). 
Vitamin D deficiency has been increasing globally, 
with a high prevalence in the Iran population (5, 6). 
Vitamin D is a steroid‐derived hormone that is 
associated with bone health and phosphate and calcium 
homeostasis (7). 1,25-dihydroxy vitamin D3 
[1,25(OH)2D3] is the hormonal form of vitamin D, 
which is involved in the regulation of many genes in 
humans through its binding to vitamin D receptor 
(VDR) in the nucleus (8). The supplementation of 
Vitamin D has been exhibited to confer benefits against 
cardiovascular and type 2 diabetes disorders, 
especially in individuals with a positive history for 
vitamin D deficiency (9-11). The serum level of 25-
hydroxyvitamin D (25(OH)D) is the best measurable 
marker for the determination of vitamin D status. Due 
to the increasing incidence of metabolic syndrome and 
vitamin D deficiency in Iran, the analysis of the 
relationships between vitamin D levels and the 
development of metabolic syndrome in different 
populations of Iran is a necessity. Our attempts to 
analyze these relationships will undoubtedly help to 
successful therapeutic interventions. The aim of this 
study is the comparative of 25 (OH) vitamin D serum 
levels in healthy individuals and patients with 




Our research was a case-control study. We 
enrolled randomly 110 women from definitive 
metabolic syndrome patients based on clinical findings 
that were recorded in Shahid Doran hospital of Shiraz 
as a case group. Also, we enrolled 130 healthy women 
randomly from Shahid Doran hospital’s staff as a 
control group. The ages of the healthy and patient 
participants were recorded. We included them if they 
had the following criteria: no usage of vitamin D 
supplement or calcium, and no recognized diseases 
associated with the deficiency of vitamin D such as 
rickets. The exclusion criteria were D vitamin 
supplementation and all recognized disorders 
associated with vitamin D. Under the National 
Cholesterol Education Program Adult Treatment Panel 
III (ATP III) criteria, metabolic syndrome was defined 
in the presence of three or more of the following 
components: waist circumference ≥102 cm in men and 
≥ 88 in women, fasting glycemia ≥100 mg/dL, serum 
triglyceride level ≥150 mg/dL, HDL cholesterol level 
<50 mg/dL in women and < 40 mg/dl in men, and 
elevated blood pressure (systolic blood pressure ≥130 
and/or diastolic blood pressure ≥85 mmHg) (12). We 
informed all participants about the purposes and details 
of this research before the start. None of the control and 
case participants were excluded from our study. This 
study was designed, compiled, and written based on the 
data recorded in the laboratory of Shahid Doran 
Hospital in Shiraz. 
Clinical measurements. After 14-12 hours of 
fasting, 10 ml of the blood sample was taken, collected, 
and sent to the hospital laboratory for measurement of 
lipid profile, FBS parameter, and 25-hydroxy vitamin 
D level. Blood samples were centrifuged at room 
temperature for 10 min at 3000 rpm. Serum 
concentrations of total cholesterol, LDL-C, FBS, 
HDL-C, and serum triglyceride were determined by 
enzymatic and colorimetric methods (Pars Azmun, 
Karaj, Iran). The level of serum 25(OH)‐vitamin D was 
determined by the ELISA method (Immunodiagnostic 
Systems, Paris, France). All experiments were done in 
Shahid Doran hospital laboratory.  
Statistical Analysis. Data analysis was 
performed by IBM SPSS Statistics, version 15 (SPSS 
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Inc, Chicago, IL). Data were analyzed using Student –
t-test and Mann-Whitney-U tests, and p< 0.05 and p< 
0.01 were considered as statistically significant. 
Results 
This study examined 130 healthy individuals 
as a control group and 110 patients with metabolic 
syndrome as a case group. All healthy and patients 
individuals in the present study were women. After 
collection and analyses of data, all participants in the 
control and case groups were divided into three 
categories deficient, insufficient and sufficient on the 
base of their measured 25-(OH) vitamin D serum 
concentrations. The mean levels of 25-(OH) vitamin D 
in the case and control group for all categories are 
shown in Table 1. As shown in Table 1, the prevalence 
rate of 25 (OH)D of sufficient, insufficient and 
deficient categories in the control group were 52 
(40%), 68 (52.3%), and 10 (7.7%), respectively.  
These numbers for patient group were 21 (19%), 78 
(71%), 11 (10%), respectively. The mean age, lipid 
profile, FBS, and vitamin D levels in both control and 
case groups are shown in Table 2.  The mean level of 
25-hydroxy vitamin D in the control group was 
28.41±9.61 ng/ml, and in the case group was 
22.17±8.53 ng/ml, and there was a significant 
difference between serum levels of vitamin D in both 
groups (P=0.01). There was not any significant 
relationship between mean age (P=0.124) level in 
control and case groups. There was also a significant 
difference between FBS (P=0.000), TG (P=0.000), 
LDL (P=0.000), Chol (P=0.000), and HDL (P=0.000) 
levels in both control and case groups. FBS, LDL, 
Chol, and TG levels were significantly higher, and 
HDL was significantly lower in the case group 
compared to the control group. Also, the relationship 
between vitamin D level and other metabolic syndrome 
parameters was investigated. In Table 3, in the study 
population, there was significant positive correlation 
between vitamin D and HDL (P=0.001, r=0.244). 
There were significant negative correlations between 
vitamin D and LDL (P=0.000, r= -0. 319), Chol 
(P=0.000, r=-0.433), TG (P=0.000, r=-0.412) and FBS 
(P=000, r=-0.451). The results of Table 3 also shows 
the relationship between other lipid parameters and 
glucose in the entire control and patient populations. In 
the population of metabolic syndrome, no significant 
Table1. The mean levels of 25(OH)D in two case and control 
groups. 




mean±SD N mean±SD N p 
25(OH)D < 
10 (ng/ml) 




20.50±4.21 78 24.74±3.09 68 0.00 
25(OH)D > 
30(ng/ml) 
35.57±4.16 21 37.67±5.54 52 0.51 
Data are represented as mean±SD. P<.05 was considered statistically significant 
Table2. The mean values of metabolic syndrome components FBS, TG, 
LDL, HDL, Chol, and VitD3. Abbreviations: FBS, fasting blood sugar; 
HDL, high-density lipoproteins; LDL, low- density lipoproteins; TG, 
triglyceride; Chol, cholesterol. VitD3, Vitamin D3. 
 Case group Control group  
 mean±SD mean±SD p-value 
Age (years) 44.30±12.08 47.09±12.60 0.124 
FBS (mg/dl) 110.38±16.71 88.34±8.53 0.000 
TG (mg/dl) 204.96±60.01 124.07±56.31 0.000 
Chol (mg/dl) 219.82±31.88 168.65±26.16 0.000 
HDL (mg/dl) 37.5616±4.63 43.20±6.50 0.000 
LDL (mg/dl) 141.27±35.61 100.63±30.34 0.000 
VitD3 (ng/ml 22.17±8.53 28.41±9.61 0.01 
Data are represented as mean±SD. P<.01 and was considered statistically significant. 
Table3. Correlations of metabolic syndrome components with vitamin D in 
whole study populations. 
  Age FBS TG Chol HDL VitD LDL 
Age 
R 1 -.040 -.040 -.063 -.005 .066 -.047 
Pvalue  .572 .572 .374 .948 .355 .509 
FBS 
R -.040 1 .342** .350** -.214** -.451** .258** 
Pvalue .572  .000 .000 .002 .000 .000 
TG 
R -.040 .342** 1 .285** -.226** -.412** -.046 
Pvalue .572 .000  .000 .001 .000 .517 
Chol 
R -.063 .350** .285** 1 -.280** -.433** .932** 
Pvalue .374 .000 .000  .000 .000 .000 
HDL 
R -.005 -.214** -.226** -.280** 1 .244** -.364** 
Pvalue .948 .002 .001 .000  .001 .000 
VitD 
R .066 -.451** -.412** -.433** .244** 1 -.319** 
Pvalue .355 .000 .000 .000 .001  .000 
LDL 
R -.047 .258** -.046 .932** -.364** -.319** 1 
Pvalue .509 .000 .517 .000 .000 .000  
**. Correlation is significant at the 0.01 level (2-tailed). 
Table4. Correlations between metabolic syndrome components and vitamin D in 
patients with metabolic syndrome. 
  Age FBS TG Chol HDL VitD LDL 
Age 
R 1 -.060 .049 -.043 .064 -.014 -.063 
Pvalue  .615 .683 .719 .593 .907 .597 
FBS 
R -.060 1 .065 -.096 .102 -.154 -.121 
Pvalue .615  .586 .418 .390 .194 .307 
TG 
R .049 .065 1 -.163 -.079 -.075 -.473** 
Pvalue .683 .586  .168 .508 .530 .000 
Chol 
R -.043 -.096 -.163 1 .102 .052 .937** 
Pvalue .719 .418 .168  .393 .662 .000 
HDL 
R .064 .102 -.079 .102 1 .066 -.013 
Pvalue .593 .390 .508 .393  .578 .914 
VitD 
R -.014 -.154 -.075 .052 .066 1 .063 
Pvalue .907 .194 .530 .662 .578  .596 
LDL 
R -.063 -.121 -.473** .937** -.013 .063 1 
Pvalue .597 .307 .000 .000 .914 .596  
**. Correlation is significant at the 0.01 level (2-tailed). 
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relationship was observed between vitamin D and 
parameters (Table 4).  
Discussion 
We found that the serum level of vitamin D, 
LDL, and HDL in patients with metabolic syndrome 
are lower than in the normal group. FBS and TG were 
significantly higher in the metabolic syndrome group 
compared to the control group, but there is any 
significant association between Chol level and age in 
the control group and patients with metabolic 
syndrome.  
Metabolic syndrome prevalence is growing 
globally because of increasing age and obesity in all 
communities around the world in the last decades (1). 
This syndrome is described by the clustering of clinical 
findings, including abdominal obesity, increased blood 
glucose levels, high TG and low HDL levels, and 
hypertension, which mostly occur together (13). The 
metabolic syndrome is related to increased risk of type 
2 diabetes and atherosclerotic cardiovascular 
morbidity and mortality (14, 15). According to NCEP-
ATP III criteria, metabolic syndrome prevalence was 
found to be 41.1% in different studies conducted in 
Iran (16). Considerable studies have focused on 
associations between vitamin D levels and the clinical 
finding of metabolic syndrome. Some reports 
demonstrate an inverse association between serum 
25(OH)D and insulin resistance, diabetes, and 
metabolic syndrome (4, 17). Nuclear vitamin D 
receptors are expressed in pancreatic β-cells, which 
may be effective in insulin synthesis and secretion. 
Vitamin D deficiency enhances the risk of insulin 
resistance, increased blood glucose, lipotoxicity, 
obesity, and the risk of cardiovascular development (4, 
18). Vitamin D deficiency can be due to inadequate 
exposure to sunlight, reduced nutritional intake of 
vitamin D or limited its absorption, increased 
catabolism of vitamin D. Also, renal and/or liver 
diseases can also prevent the conversion of vitamin D 
to its active form (4). 
A meta-analysis of 28 kinds of research 
(including 99745 participants) reported that high levels 
of serum 25(OH)D were associated with a 55%, 51%, 
and 33% decreased risk of diabetes, metabolic 
syndrome, and cardiovascular disease, respectively 
(19). Gagnon et al. studied 4164 adults (mean age 50 
years) and reported that serum 25(OH)D was inversely 
associated with waist circumference, TG, and FBS 
serum levels but not with HDL-C level and blood 
pressure (20, 21). Vitamin D deficiency has a high 
prevalence among the Iranian population, and inverse 
associations between serum vitamin D and numerous 
skeletal and non-skeletal diseases have been reported 
in the Iranian women population (22, 23). Women with 
vitamin D deficiency noticeably suffer skeletal and 
non-skeletal disorders such as osteoporosis, fractures, 
and diabetes, which may be improved by interventions 
such as vitamin D (5, 24). A significant improvement 
in serum FBS and insulin has been reported after 
treatment with vitamin D in 100 patients with type 2 
diabetes in an Arak diabetes clinic (23). In the present 
study, we investigate serum levels of 25(OH)D, FBS, 
Chol, TG, LDL, and HDL in patients with metabolic 
syndrome compared to the control group. All subjects 
were divided into three categories on the base of their 
measured 25-(OH) vitamin D serum levels. 25(OH)D 
levels as sufficient (> 30), insufficiency (20-29 ng/mL) 
and deficiency (< 20 ng/mL). Insufficiency of 25-(OH) 
vitamin D has the highest rate among both patient and 
control groups. FBS, LDL, Chol, and TG were 
significantly higher, and HDL was significantly lower 
in the metabolic syndrome group compared to the 
control group. We also explored the correlations 
between metabolic parameters and vitamin D in the 
whole studied population and metabolic syndrome 
patients referred to Shiraz's Shahid Doran Hospital. In 
the whole population, there was a significant positive 
correlation between serum vitamin D and HDL, but 
there was a significant negative correlation between 
serum vitamin D and LDL, Chol, TG, and FBS, 
respectively. However, no significant relationship was 
observed between vitamin D and metabolic parameters 
in patients with  metabolic syndrome. 
Conclusion  
In conclusion, the results of current research 
indicated that there is a significant association between 
metabolic syndrome and 25(OH)D levels. The highest 
rates for the patient with metabolic syndrome belong 
to insufficiency categories (20-29 ng/mL). The finding 
of this study also showed that 25(OH)D levels were 
significantly lower in the metabolic syndrome group 
compared to the control group.  
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